FORM 6-K

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934


For period ending May 22 2008

GlaxoSmithKline plc
(Name of registrant)

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


Form 20-F x Form 40-F
 --


Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x
  --

 

GlaxoSmithKline plc

Document 
r
egarding 
special r
esolutions 
passed at the 
Company's 
A
nnual General 
M
eeting
on 
21
 
May 200
8


Two copies of all 
the 
resolutions passed 
under 
special business at the 
Company's 
AGM on 
21
 May 200
8
 
have been submitted to the 
UK Listing Authority 
and will shortly be available 
for inspection via the UK Listing Authority
's 
D
ocument 
V
iewing 
Fa
c
ility situated at:

Financial Services Authority
25 North Colonnade
Canary Wharf
London
E14 5HS

Tel: 020 7066 1000
.



S M Bicknell
Company Secretary

22
 
May 200
8

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 

                                                             GlaxoSmithKline plc
                                                                    (Registrant)

Date: May 22 2008       

                                                                                                       By: VICTORIA WHYTE
                                                                                                                                                                ------------------
                                                              Victoria Whyte
                                                 Authorised Signatory for and on
                                                   behalf of GlaxoSmithKline plc